Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries no "tag".
The protein has a calculated MW of 13.8 kDa.
>95% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in PBS, pH7.4.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Tau-441 K18 (P301L) monomer on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Transmission electron microscopy (TEM) of Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free (Cat. No. TAU-H5113). Fibril structure is visible on negative stain TEM images of TAU-H5113 (Routinely tested).
Price(USD) : $375.00
Price(USD) : $1700.00
Price(USD) : $3090.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Flortaucipir F18 | 18F-AV-1451; T807; F-18-AV-1451 | Approved | Siemens Medical Solution | Tauvid | United States | Alzheimer Disease | Avid Radiopharmaceuticals Inc | 2020-05-28 | Tauopathies; Neurodegenerative Diseases; Corticobasal degeneration; Frontotemporal Dementia; Cognition Disorders; Diagnostic agents; Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease; Supranuclear Palsy, Progressive; Dementia; Pick Disease of the Brain; Aphasia, Primary Progressive; Chronic Traumatic Encephalopathy; Brain Concussion; Depression; Brain Injuries, Traumatic; Brain Injuries | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Alzheimer Disease; Parkinson Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
Florzolotau (Aprinoia Therapeutics) | [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607; [18F]APN-1607; [18F]MNI-958; APN-0000455; F0-PBB3; PM-PBB3 | Phase 3 Clinical | Aprinoia Therapeutics Ltd | Supranuclear Palsy, Progressive; Nerve Degeneration; Alzheimer Disease; Cognitive Dysfunction; Diagnostic agents; Cognition Disorders | Details |
E-2814 | E-2814 | Phase 3 Clinical | Eisai Co Ltd | Dementia; Alzheimer Disease | Details |
Izaflortaucipir F-18 | PI-2620; 18F-PI-2620; [18F]PI-2620 | Phase 3 Clinical | Piramal, Ac Immune Sa | Supranuclear Palsy, Progressive; Brain Injuries, Traumatic; Opioid-Related Disorders; Frontotemporal Lobar Degeneration; Alzheimer Disease; Cognitive Dysfunction | Details |
XTR-006 | XTR-006 | Phase 3 Clinical | Beijing Xiantong International Technology Co Ltd | Tauopathies; Alzheimer Disease | Details |
Zagotenemab | LY-3303560 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
Posdinemab | JNJ-3657; JNJ-63733657 | Phase 2 Clinical | Johnson & Johnson Innovative Medicine | Dementia; Alzheimer Disease; Cognitive Dysfunction | Details |
[18F]GTP-1 | [18F]GTP-1 | Phase 2 Clinical | Genentech Inc | Alzheimer Disease | Details |
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
ISIS-814907 | BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX | Phase 2 Clinical | Biogen Inc, Ionis Pharmaceuticals Inc | Dementia; Cognitive Dysfunction; Alzheimer Disease | Details |
Tilavonemab | C2N-8E12; ABBV-8E12 | Phase 2 Clinical | C2n Diagnostics Llc | Supranuclear Palsy, Progressive; Alzheimer Disease | Details |
Semorinemab | MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
APN-1701 | [18F]AM-PBB3; 18F-AM-PBB3; APN-1701 | Phase 2 Clinical | National Institute Of Radiological Sciences, Aprinoia Therapeutics Ltd | Nerve Degeneration; Alzheimer Disease | Details |
Anti-tau antibody (Prothena) | PRX-005; BMS-986446 | Phase 2 Clinical | Prothena | Alzheimer Disease; Frontotemporal Dementia | Details |
Bepranemab | UCB-0107; RG6416 | Phase 2 Clinical | Ucb | Supranuclear Palsy, Progressive; Alzheimer Disease | Details |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
PNT-001 | PNT-001 | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Brain Injuries, Traumatic; Alzheimer Disease | Details |
ReS19-T | ReS19-T | Phase 1 Clinical | Remynd | Alzheimer Disease | Details |
Mecripyrine Hydrochloride | SCR-1693; Y-1A; Y-1 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd, NeuroDawn Pharmaceutical Co Ltd | Brain Neoplasms; Alzheimer Disease | Details |
Lu-AF87908 | Lu-AF87908; Lu-AF-87908 | Phase 1 Clinical | H. Lundbeck A/S | Alzheimer Disease | Details |
RDC-5 | RDC-5 | Phase 1 Clinical | Chronos Therapeutics Ltd | Amyotrophic Lateral Sclerosis | Details |
MC-1 (Lilly) | MC-1 (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
VY-TAU-01 | VY-TAU-01; VY-TAU01 | Phase 1 Clinical | Voyager Therapeutics Inc | Alzheimer Disease | Details |
OLX-07010 | OLX07010 | Phase 1 Clinical | Oligomerix Inc | Supranuclear Palsy, Progressive; Alzheimer Disease; Dementia; Neurodegenerative Diseases | Details |
Protollin | Phase 1 Clinical | Brigham and Women's Hospital Inc | Alzheimer Disease | Details | |
AB-19 (AUTOTAC Bio) | AB-19 (AUTOTAC Bio) | Phase 1 Clinical | Autotac Bio Inc | Supranuclear Palsy, Progressive | Details |
AB-12 po (AUTOTAC Bio) | AB-12 po | Phase 1 Clinical | Autotac Bio Inc | Alzheimer Disease | Details |
[89Zr]Zr-DFO-BIIB080 | [89Zr]Zr-DFO-ISIS-814907; [89Zr]Zr-DFO | Phase 1 Clinical | Biogen Inc | Details | |
DA-7503 | DA-7503 | Phase 1 Clinical | Dong-A ST Co Ltd | Details | |
ADEL-Y01 | ADEL-Y01 | Phase 1 Clinical | Oscotec Inc, ADEL Inc | Tauopathies; Alzheimer Disease | Details |
MK-2214 | MK-2214 | Phase 1 Clinical | Merck Sharp & Dohme LLC | Alzheimer Disease | Details |
APNmAb-005 | APNmAb-005 | Phase 1 Clinical | Aprinoia Therapeutics Ltd | Nerve Degeneration; Alzheimer Disease; Tauopathies | Details |
NIO-752 | NIO-752 | Phase 1 Clinical | Novartis Pharma Ag | Supranuclear Palsy, Progressive; Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases | Details |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
BIIB-076 | NI-105; BIIB-076 | Phase 1 Clinical | Neurimmune Ag | Alzheimer Disease | Details |
11C-PBB3 | 11C-PBB3 | Clinical | National Institute Of Radiological Sciences | Alzheimer Disease | Details |
This web search service is supported by Google Inc.